Transcatheter aortic valve implantation (TAVI, also called TAVR) replaces a narrowed aortic valve with a biological valve delivered by catheter, without opening the chest, usually through the femoral artery. Under the 2021 ESC/EACTS guidelines it is preferred from age 75 or when surgical risk is high; in younger, low-risk patients surgical valve replacement is generally recommended. The procedure takes 1 to 2 hours and the hospital stay is 2 to 5 days. In Turkey the price starts at about $20,600, depending on the valve and the patient's situation.
You send us your file (echocardiogram, CT scan, coronary angiogram, medication list). We forward it to the cardiologist and cardiac surgeon at the partner clinic, who assess the case with the multidisciplinary Heart Team, and then we send you a detailed quote. We also arrange airport pickup, transfers, an interpreter and 7-day assistance.
The main criterion is the Heart Team's decision after a cardiac CT scan, together with how many TAVI procedures the clinic performs each year. The PARTNER 3 and Evolut Low Risk trials provide reference data on heart valve disease treated with this technique.
How much does TAVI cost in Turkey?
The price of TAVI in Turkey is about $20,600 to $30,800, depending on the type of valve (Edwards SAPIEN 3, Medtronic Evolut or other) and the complexity of the case. For reference, surgical valve replacement costs $12,000 to $18,000.
What the price includes:
- Pre-operative consultation and assessments.
- Hospital fees and stay.
- Anesthesia and the procedure itself.
- Initial post-operative monitoring and follow-up.
The valve type, the access route, the time in intensive care and the clinic can change the total. The quote is based on your file. We send your medical file to the cardiologist and surgeon at the partner clinic, who assess it with the Heart Team, then we send you a detailed quote and arrange airport pickup, transfers and an interpreter.
Risks and Side Effects
Possible complications include conduction disorders that may require a pacemaker (about 17% at 30 days in the Evolut Low Risk trial with a self-expanding valve, less often with other valve types),stroke (about 3% at 30 days in the same trial),bleeding and vascular complications at the access site, moderate or severe paravalvular leak (about 3.5% in Evolut Low Risk),kidney injury, infection and, rarely, rupture of the aortic annulus requiring emergency surgery. A mild paravalvular leak is much more common (about 29% at one year in PARTNER 3) and usually needs no treatment.
Groin pain or bruising and fatigue are expected in the first days. After discharge, seek urgent care for chest pain, shortness of breath, fainting, weakness in a limb, speech problems or fever. Risk depends on age, other conditions and anatomy; the cardiology team assesses it before the procedure.
























































